Weekly paclitaxel and nedaplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer: A phase I/II study

Japanese Journal of Clinical Oncology

Volumn 34, Issue 11, 2004, Pages 647-653

  Hasegawa, Yukihiro ^a   Takanashi, Shingo ^a   Okudera, Koichi ^a   Aoki, Masahiko ^a   Basaki, Kiyoshi ^a   Kondo, Hidehiro ^a   Takahata, Takenori ^a   Yasui Furukori, Norio ^a   Tateishi, Tomonori ^a   Abe, Yoshinao ^a   Okumura, Ken ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

Nedaplatin; Non small cell lung cancer; Paclitaxel; Pharmacokinetics; Pulmonary toxicity; Radiotherapy

Indexed keywords

NEDAPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; ESOPHAGITIS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAXIMUM TOLERATED DOSE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; ADULT; AGED; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; LUNG; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; RADIATION DOSE; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PACLITAXEL; RADIOTHERAPY DOSAGE; SURVIVAL RATE;

EID: 16644388310     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyh119     Document Type: Article

References (35)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-6.
2. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, et al. SEER Cancer Statistics Review, 1975-2000. Bethesda, MD: National Cancer Institute, 2003.
3. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
4. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-7.
5. Schaake-Koning C, van den Bogaert W, Dalesio O, Festen J, Hoogenhout J, van Houtte P, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992;326:524-30.
6. Le Chevalier T, Arriagada R, Quoix E, Ruffle P, Martin M, Tarayre M, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991;83:417-23.
7. Dillman R, Seagren S, Propert K, Guerra J, Eaton W, Perry M, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 1990;323:940-5.
8. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995;311:899-909.
9. Choy H, Akerley W, Safran H, Clark J, Rege V, Papa A, et al. Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer. J Clin Oncol 1994;12:2682-6.
10. Choy H, Safran H, Akerley W, Graziano SL, Bogart JA, Cole BF. Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Clin Cancer Res 1998;4:1931-6.
11. Rosenthal DI, Lee JH, Sinard R, Yardley DA, Machtay M, Rosen DM, et al. Phase I study of paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 2001;19:1363-73.
12. Frasci G, Comella P, Scoppa G, Guida C, Gravina A, Fiore F, et al. Weekly paclitaxel and cisplatin with concurrent radiotherapy in locally advanced non-small-cell lung cancer: a phase I study. J Clin Oncol 1997;15:1409-17.
13. Choy H, Akerley W, Safran H, Graziano S, Chung C, Williams T, et al. Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol 1998;16:3316-22.
14. Lau D, Leigh B, Gandara D, Edelman M, Morgan R, Israel V, et al. Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium phase II trial. J Clin Oncol 2001;19:442-7.
15. Shiratori O, Kanai H, Uchida N, Takeda Y, Totani T, Sato K. Antitumor activity of 254-S, a platinum complex, in rodents. Recent Adv Chemother 1985;635.
16. Totani T, Aono K, Adachi Y, Komura M, Shiratori O, Sato K. Bidentate hydroxycarboxylic acid platinum (II) complexes with antitumoractivity. In: Nicolini M, editor. Platinum and Other Metal Coordination Compounds in Cancer Therapy. Boston: Martinus Nijhoff, 1987;744.
17. Kelsen D, Scher H, Alcock N, Leyland-Jones B, Donner A, Williams L, et al. Phase I clinical trial and pharmacokinetics of 4′-carboxyphthalato( 1,2-diaminocyclohexane)platinum(II). Cancer Res 1982;42:4831-5.
18. Fukuda M, Shinkai T, Eguchi K, Sasaki Y, Tamura T, Ohe Y, et al. Phase II study of (glycolate-O,O′)diammineplatinum(II), a novel platinum complex, in the treatment of non-small-cell lung cancer. Cancer Chemother Pharmacol 1990;26:393-6.
19. Ita M, Okafuji M, Fukuda K, Mitsuoka K, Hanakita T, Hayatsu Y. Concurrent chemoradiotherapy with new platinum compound nedaplatin in oral cancer. Oral Oncol 2003;39:144-9.
20. Nemoto K, Matsushita H, Ogawa Y, Takeda K, Takahashi C, Britton KR, et al. Radiation therapy combined with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for untreated and recurrent esophageal cancer. Am J Clin Oncol 2003;26:46-9.
21. Ohtsu T, Sasaki Y, Tamura T, Miyata Y, Nakanomyo H, Nishiwaki Y, et al. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. Clin Cancer Res 1995;1:599-606.
22. Ishibashi T, Yano Y, Oguma T. Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients. Br J Clin Pharmacol 2003;56:205-13.
23. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
25. Sause W, Scott C, Taylor S, Johnson D, Livingston R, Komaki R, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995;87:198-205.
26. Jeremic B, Shibamoto Y, Acimovic L, Djuric L. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol 1995;13:452-8.
27. Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/ etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol 1996;14:1065-70.
28. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-9.
29. Antonia SJ, Wagner H, Williams C, Alberts M, Hubbell D, Robinson L, et al. Concurrent paclitaxel/cisplatin with thoracic radiation in patients with stace IIIA/B non-small cell carcinoma of the lung. Semin Oncol 1995;22(4 Suppl 9):34-7.
30. Belani CP, Aisner J, Bahri S, Jett J, Day R, Capazolli MJ, et al. Chemoradiotherapy in non-small cell lung cancer: paclitaxel/carboplatin/ radiotherapy in regionally advanced disease. Semin Oncol 1996;23(6 Suppl 16):113-6.
31. Comella G, Frasci G, Scoppa G, Guida C, Gravina A, Fiore F, et al. Weekly paclitaxel/cisplatin with concurrent radiotherapy in patients with locally advanced non-small cell lung cancer: a phase I study. Semin Oncol 1997;24(4 Suppl 12):S12-113-6.
32. Solomon B, Ball DL, Richardson G, Smith JG, Millward M, MacManus M, et al. Phase I/II study of concurrent twice-weekly paclitaxel and weekly cisplatin with radiation therapy for stage III non-small cell lung cancer. Lung Cancer 2003;41:353-361.
33. Taghian AG, Assaad SI, Niemierko A, Kuter I, Younger J, Schoenthaler R, et al. Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel. J Natl Cancer Inst 2001;93:1806-11.
34. Lopes NM, Adams EG, Pitts TW, Bhuyan BK. Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 1993;32:235-42.
35. Liebmann J, Cook J, Fisher J, Teague D, Mitchell J. In vitro studies of taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst 1994;86:441-6.